Skip to main content

Table 1 Comparison of clinical manifestations between patients with AML in low and high BDH2 expression groups a

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variables Total (n = 113) Low BDH2, expression, (n = 57) High BDH2, expression, (n = 56) P
Sexb 113 57 56 0.467
  Male 64 23 26  
  Female 49 34 30  
Age (years)c 54.5 (21–86) 48 (22–86) 57 (21–85) 0.193
Laboratory datac     
  WBC, ìL−1 30,830 37,615 24,370 (600–243,290) 0.452
(300–296,300) (300–216,820)
  Hb, g/dL 8.3 8.3 8.4 0.365
(4.2–15.6) (4.4–14.3) (4.2–15.6)
  Platelet, ×1,000/ìL 42 44.5 41 0.582
(3–369) (4–175) (3–369)
  Blast, ìL−1 20,188.5 13,074.15 26,001 0.172
(0–287,411) (126–145,572.7) (0–287,411)
  Blast in BM, % 74.8% (24.8%–97.4%) 70.8% (24.8%–94.7%) 79% (27.2%–94.4%) 0.424
  CD34 (+) in BM, % 31.1% 29.5% 33.25% (0%–99.5%) 0.272
(0%–99.9%) (0%–99.9%)
FABb     
  M0 3 1 (1.75%) 2 (2.44%) 0.057
  M1 28 8 (13.89%) 20 (43.90%)  
  M2 47 25 (47.23%) 22 (34.15%)  
  M3 0 0 (0%) 0 (0%)
  M4 23 15 (23.61%) 9 (14.63%)  
  M5 7 6 (9.72%) 1 (0%)  
  M6 0 0 (0%) 0 (0%)  
  M7 4 2 (2.78%) 2 (4.88%)
  Undetermined 0 0 (0%) 0 (0%)  
Induction responsebd     
  CR 61 (70.93%) 37 (80.42%)f 24 (60%)g 0.032*
  PR and Refractory   32 20  
  Induction death   1 0  
Reach CR timee     
  38 ± 38.0 40.5 ± 44.3 36 ± 29.7 0.526
  1. aThe median value of BDH2 expression in the total population was used as the cutoff level of 9.006 to define low- and high-expression groups.
  2. bNumber of patients (%).
  3. cMedian (range).
  4. dOnly the 86 patients who received conventional intensive induction chemotherapy, and then consolidation chemotherapy if CR was achieved, were included in the analyses.
  5. ePatients received conventional intensive induction chemotherapy and achieved CR, median, days ± S.D.
  6. fOnly 46 patients received I3A7.
  7. gOnly 40 patients received I3A7 (Idarubicin and Ara-C).
  8. *Statistically significant (P < 0.05).